Literature DB >> 7957549

Genetically determined sparteine oxidation polymorphism in a Polish population.

K Orzechowska-Juzwenko, J Pawlik, P Niewiński, P Milejski, J Dembowski, J Turek, A Goździk, L Swiebodzki, Z Hora.   

Abstract

The genetic oxidation polymorphism was determined in 160 healthy Polish volunteers from the south-west of Poland (Wrocław region), using sparteine as a model drug. The results of a Polish population study revealed a bimodal distribution of the sparteine metabolic ratio and showed the existence of two oxidation phenotypes designated as extensive and poor metabolizers. The frequency of poor metabolizers in our study (8.8%) compares well with most results of poor oxidation metabolizers in Caucasian populations.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7957549     DOI： 10.1007/BF00191917

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  30 in total

Review 1.  Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism.

Authors:  Y Horai; T Ishizaki
Journal:  Ration Drug Ther       Date:  1988-06

2.  The genetic polymorphism of sparteine metabolism.

Authors:  M Eichelbaum; K P Reetz; E K Schmidt; C Zekorn
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

3.  Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

Authors:  Y C Lou; L Ying; L Bertilsson; F Sjöqvist
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

4.  Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.

Authors:  W D Paar; H Schuhler; R Fimmers; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

6.  Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.

Authors:  J Kallio; R Lindberg; R Huupponen; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 7.  Clinical consequences of polymorphic drug oxidation.

Authors:  G Alván
Journal:  Fundam Clin Pharmacol       Date:  1991       Impact factor: 2.748

8.  Sparteine oxidation polymorphism in Denmark.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-11

9.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.

Authors:  Y Horai; T Ishizaki; M Eichelbaum; K Hashimoto; K Chiba; H J Dengler
Journal:  Xenobiotica       Date:  1988-09       Impact factor: 1.908
View more
  1 in total

1.  Debrisoquine hydroxylation in a Polish population.

Authors:  P K Kunicki; D Sitkiewicz; A Pawlik; V Bielicka-Sulzyc; E Borowiecka; B Gawrońska-Szklarz; R Sterna; H Matsumoto; M Radziwoń-Zaleska
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.